Cell Press | Jotup

Mursla Bio Presents Breakthrough Liquid Biopsy Technology for Extracellular Vesicles in Cell Press

Retrieved on:

Lunedì, Giugno 3, 2024

Biotechnology, Health, Science, Research, Oncology, EV, Cell Press, Seminal vesicles, Trial of the century, Liver cancer, EVS, Disease, Blood, Cell, Medical imaging

Mursla Bio is pleased to announce the publication of its latest peer-reviewed paper in iScience, an interdisciplinary journal of the esteemed Cell Press.

Key Points:

Mursla Bio is pleased to announce the publication of its latest peer-reviewed paper in iScience, an interdisciplinary journal of the esteemed Cell Press.
The paper showcases Mursla Bio’s breakthrough technology for the analysis of extracellular vesicles (EV) sub-types within biofluids such as blood.
EVs are important actors in intercellular communication and are set to transform the field of disease diagnostics.
Mursla Bio anticipates the publication of additional peer-reviewed papers supporting its clinical study on liver cancer, which is expected to complete later this year.

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

Retrieved on:

Martedì, Maggio 28, 2024

HEIDELBERG, Germany, May 28, 2024 - (ACN Newswire) - German independent research institute BioMed X announces the successful completion of its second neuroscience project in partnership with Boehringer Ingelheim in the field of psychiatric disorders.

Key Points:

HEIDELBERG, Germany, May 28, 2024 - (ACN Newswire) - German independent research institute BioMed X announces the successful completion of its second neuroscience project in partnership with Boehringer Ingelheim in the field of psychiatric disorders.
The data resulting from this project have been acquired by Boehringer Ingelheim, where this research will be continued, potentially paving the way for novel therapies.
This research project was launched in 2020 at the BioMed X Institute in Heidelberg and led by Dr. Ebru Ercan Herbst, now a professor at Reutlingen University, Germany.
Dr. Christian Tidona, Managing Director & Founder of the BioMed X Institute: "This is already our second successfully completed project with Boehringer Ingelheim in the field of psychiatry.

Major Breakthrough Unveiled: Transformative Advances in Sustainable EV Battery Repurposing

Retrieved on:

Mercoledì, Maggio 8, 2024

Lithium, Stanford University, Climate change, BNEF, Health, LG, Cell Press, Research, BESS, Life, Wind, EV, Battery management system, Chemistry, Multimedia, BMS, Longevity, Growth, Electric battery

In recent years, there has been a significant increase in the deployment of battery energy storage systems worldwide.

Key Points:

In recent years, there has been a significant increase in the deployment of battery energy storage systems worldwide.
However, despite the increasing adoption of battery energy storage systems, there are challenges associated with the lifespan of batteries.
This groundbreaking research has significant implications for the energy storage industry, as it opens up new possibilities for extending the battery lifespan.
Unlike traditional BMS, which are often limited by battery chemistry and source, the new technology is adaptable to a wide range of battery types and conditions.

Five Talented Women Scientists from the Global South Win OWSD-Elsevier Foundation Research Prize for Their Work on New Ways to Tackle Water Quality Issue

Retrieved on:

Giovedì, Marzo 21, 2024

The 2024 OWSD-Elsevier Foundation Awards have recognized women-led science from more than 20 low- and middle-income countries since 2013

Key Points:

The prize also acknowledges the scientists’ commitment to leadership, mentoring and engagement within their communities, including the translation of research into actionable insights for stakeholders.
We are so proud of them and are sure this prize is just one step on their path to success."
By offering this prize, we want to spotlight the important research undertaken by the women who've become inspiring role models for communities most affected by this issue."
To find out how the OWSD-Elsevier Foundation Award helps shape our understanding of the global South, read more about the 2023 winners here .

ThinkCyte advances biopharma phenotypic drug discovery programs with publication and presentation milestones

Retrieved on:

Lunedì, Aprile 1, 2024

University, Automation, Gene, Drug discovery, Cell Press, DNA, Artificial intelligence, SLAS, Society, Laboratory, CRISPR, Cell

TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.

Key Points:

TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.
The new approach allows for not only faster drug screening, but also opens the door to use a host of new morphology-driven phenotypes in drug discovery campaigns.
In December, the company was also profiled in a special edition of Cell Press highlighting the emerging uses of AI in drug discovery screening.
"Our biopharma customers are looking to integrate new technologies to expand their phenotypic drug screening programs," said Janette Phi, Chief Business Officer at ThinkCyte.

ThinkCyte advances biopharma phenotypic drug discovery programs with publication and presentation milestones

Retrieved on:

Lunedì, Aprile 1, 2024

University, Automation, Gene, Drug discovery, Cell Press, DNA, Artificial intelligence, SLAS, Society, Laboratory, CRISPR, Cell

TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.

Key Points:

TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.
The new approach allows for not only faster drug screening, but also opens the door to use a host of new morphology-driven phenotypes in drug discovery campaigns.
In December, the company was also profiled in a special edition of Cell Press highlighting the emerging uses of AI in drug discovery screening.
"Our biopharma customers are looking to integrate new technologies to expand their phenotypic drug screening programs," said Janette Phi, Chief Business Officer at ThinkCyte.

GeNeuro and Verily Collaborate to Advance Long-COVID Research

Retrieved on:

Giovedì, Ottobre 19, 2023

Through this collaboration, GeNeuro will partner with Verily to build on results published earlier this year in Cell Press , which evidenced the in vitro activation of HERV-W by SARS-CoV-2 in susceptible individuals and the correlation between W-ENV protein levels in serum and lymphocytes with COVID-19 severity.

Key Points:

Through this collaboration, GeNeuro will partner with Verily to build on results published earlier this year in Cell Press , which evidenced the in vitro activation of HERV-W by SARS-CoV-2 in susceptible individuals and the correlation between W-ENV protein levels in serum and lymphocytes with COVID-19 severity.
“Our research indicates that W-ENV contributes to COVID-19 disease severity and may explain manifestations of long-COVID,” said Dr. Hervé Perron, Chief Scientific Officer of GeNeuro.
Both solutions are part of Verily’s broader suite of products built to deliver on the promise of precision health and harness the power of richer, more diverse datasets to accelerate medical research.
“We are excited to partner with GeNeuro to advance our shared belief that identification of actionable biomarkers early in disease can advance precision health and save lives,” said Charlie Kim, Head of Molecular Science at Verily.

Ørsted enters its first UK solar project

Retrieved on:

Sabato, Settembre 16, 2023

Senior, Cell Press, NSIP, Electricity, DCO, Government, Wind, Acquisition, Solar energy, Duncan Clark, Renewable energy, Carrigaline

Ørsted has entered its first solar project in the UK.

Key Points:

Ørsted has entered its first solar project in the UK.
Once operational, the 740 MW solar farm will generate enough clean, renewable electricity to power up to 200,000 homes, making it one of the largest solar farms in the country.
PS Renewables and Ørsted are targeting a commercial operation date for the One Earth Solar Farm before 2030.
Ørsted already operates 420 MW of onshore wind in the UK and Ireland, producing enough green electricity to power more than 275,000 homes.

The DEAL Consortium and Elsevier Announce Transformative Open Access Agreement for Germany

Retrieved on:

Mercoledì, Settembre 6, 2023

Communication, ScienceDirect, North Pacific Marine Science Organization, Freie Erde, Research, Science, Organization, Cell Press, DEAL, Publication, MBH, Reading, Cell, Deals, Knowledge, Pharmaceutical industry, Publishing, Elsevier, Lancet

Berlin, Germany--(Newsfile Corp. - September 6, 2023) - The DEAL Consortium , representing the German research institutions, and Elsevier , a global leader in scientific information and data analytics, are delighted to announce a transformative open access agreement for Germany.

Key Points:

Berlin, Germany--(Newsfile Corp. - September 6, 2023) - The DEAL Consortium , representing the German research institutions, and Elsevier , a global leader in scientific information and data analytics, are delighted to announce a transformative open access agreement for Germany.
In addition, institutions will receive discounts on the list prices for their researchers' publications in fully open access Elsevier journals.
The agreement fulfils the key objectives set out by the Alliance of Science Organizations in Germany for the DEAL negotiations in enabling open access publishing and reading across Elsevier’s portfolio.
The DEAL Consortium and Elsevier worked together collaboratively and pragmatically to support Germany’s world-leading academic and science organizations achieve their research goals for the benefit of society.

REX American Resources Reports Fiscal 2023 Second Quarter Net Income Per Share Attributable to REX Common Shareholders of $0.52

Retrieved on:

Mercoledì, Agosto 30, 2023

Sustainability, Energy, Environment, Oil, Gas, Carbon, Corn oil, REX American Resources, Cell Press, Ethanol, COVID-19, Tax, Plant, Navigator, Investment, Webcast, Occult, REX, Renewable energy, Q2

REX’s Q2 ‘23 net sales and revenue were $212.0 million compared with $240.3 million in Q2 ‘22.

Key Points:

REX’s Q2 ‘23 net sales and revenue were $212.0 million compared with $240.3 million in Q2 ‘22.
Net income attributable to REX shareholders was $9.1 million in Q2 ‘23 compared with $11.2 million in Q2 ‘22.
Q2 ‘23 basic and diluted net income per share attributable to REX common shareholders was $0.52, compared to $0.63 per share in Q2 ‘22.
REX American Resources’ Chief Executive Officer, Zafar Rizvi, commented, “Our focus on operational efficiency resulted in REX delivering its twelfth consecutive quarter of profitability.